Role of purging in PBSC transplantation for neuroblastoma
Mené sur 495 patients atteints d'un neuroblastome à haut risque avant l'âge de 30 ans, cet essai de phase III évalue, du point de vue de la survie sans événement, l'intérêt d'une purge immunomagnétique des cellules souches du sang périphérique avant une greffe autologue des cellules souches
The story told by Susan Kreissman and colleagues in The Lancet Oncology about purging—the removal of selected cells—in peripheral blood stem-cell (PBSC) transplantations is an old one, but it remains one of the most interesting and controversial issues in paediatric oncology. Almost 20 years ago, Malcolm Brenner's group showed that marrow cells from patients with neuroblastoma in remission could be marked by a neomycin-resistance gene and could be detected after relapse in and outside the bone ma ...
The Lancet Oncology , commentaire, 2012